AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 9627067 — intervention group
Group type: COMPARATOR
Intervention: Standard method (without CPR-plus)
Number of subjects: 40
Study 7833227 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythromycin 500 mg orally three times a day for 6 days followed by 7.5 mg zopiclone
Number of subjects: 10
Study 7833227 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 2901220 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine 150 mg
Number of subjects: 8
Study 2901220 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine 300 mg
Number of subjects: 8
Study 2901220 — intervention group
Group type: EXPERIMENTAL
Intervention: Famotidine 20 mg
Number of subjects: 8
Study 2901220 — intervention group
Group type: EXPERIMENTAL
Intervention: Famotidine 40 mg
Number of subjects: 8
Study 2901220 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 2901220 — intervention group
Group type: COMPARATOR
Intervention: Ranitidine 150 mg vs Ranitidine 300 mg
Number of subjects: 8
Study 2901220 — intervention group
Group type: COMPARATOR
Intervention: Famotidine 20 mg vs Famotidine 40 mg
Number of subjects: 8
Study 29758071 — intervention group
Group type: EXPERIMENTAL
Intervention: Participatory learning and action (PLA) intervention
Number of subjects: 4030
Study 29758071 — intervention group
Group type: EXPERIMENTAL
Intervention: Subsequent exposure to PLA groups
Number of subjects: 4030
Study 28830555 — intervention group
Group type: EXPERIMENTAL
Intervention: Work-focused cognitive behavioral therapy (6 sessions) and a small workplace intervention
Number of subjects: 163
Study 28830555 — intervention group
Group type: COMPARATOR
Intervention: Control group A (clinical examination)
Number of subjects: 163
Study 28830555 — intervention group
Group type: COMPARATOR
Intervention: Control group B (no offers at the department)
Number of subjects: 163
Study 25297643 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic vitamin K (single dose)
Number of subjects: 120
Study 25297643 — intervention group
Group type: COMPARATOR
Intervention: No prophylactic vitamin K (control group)
Number of subjects: 120
Study 23244776 — intervention group
Group type: EXPERIMENTAL
Intervention: Low habit strength group
Number of subjects: 1836
Study 23244776 — intervention group
Group type: EXPERIMENTAL
Intervention: Medium habit strength group
Number of subjects: 1836
Study 23244776 — intervention group
Group type: EXPERIMENTAL
Intervention: High habit strength group
Number of subjects: 1836
Study 23244776 — intervention group
Group type: EXPERIMENTAL
Intervention: Strong PA habit group
Number of subjects: 1836
Study 21372622 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Group Therapy (CBGT) added to Treatment as Usual (TAU)
Number of subjects: 50
Study 21372622 — intervention group
Group type: COMPARATOR
Intervention: Treatment as Usual (TAU) alone
Number of subjects: 50
Study 18081756 — intervention group
Group type: EXPERIMENTAL
Intervention: Phonology with Reading (P + R) programme
Number of subjects: 152
Study 18081756 — intervention group
Group type: COMPARATOR
Intervention: Oral Language (OL) programme
Number of subjects: 152
Study 17068786 — intervention group
Group type: EXPERIMENTAL
Intervention: Active rTMS (1Hz, 1,200 pulses)
Number of subjects: 21
Study 17068786 — intervention group
Group type: COMPARATOR
Intervention: Sham rTMS
Number of subjects: 21
Study 12496571 — intervention group
Group type: EXPERIMENTAL
Intervention: Closed suction drainage in the right breast
Number of subjects: 49
Study 12496571 — intervention group
Group type: COMPARATOR
Intervention: No closed suction drainage in the left breast
Number of subjects: 49
Study 10833090 — intervention group
Group type: EXPERIMENTAL
Intervention: Pan+Amo+Cla (40 mg b.i.d. Pantoprazole, 1 g b.i.d. Amoxicillin, 500 mg b.i.d. Clarithromycin)
Number of subjects: 150
Study 10833090 — intervention group
Group type: COMPARATOR
Intervention: RBC+Amo+Cla (400 mg b.i.d. Ranitidine bismuth citrate, 1 g b.i.d. Amoxicillin, 500 mg b.i.d. Clarithromycin)
Number of subjects: 150
Study 10183331 — intervention group
Group type: EXPERIMENTAL
Intervention: Certified mail
Number of subjects: 409
Study 10183331 — intervention group
Group type: COMPARATOR
Intervention: First-class mail
Number of subjects: 409
Study 7979074 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural infusion of bupivacaine 75 mg, clonidine 150 micrograms, and diamorphine 5 mg in 60 ml normal saline at 1-4 ml/h for 24-48 hours preoperatively and maintained for at least 3 days postoperatively
Number of subjects: 24
Study 7979074 — intervention group
Group type: COMPARATOR
Intervention: On-demand opioid analgesia
Number of subjects: 24
Study 7979074 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural infusion of bupivacaine, clonidine, and diamorphine
Number of subjects: 24
Study 2690971 — intervention group
Group type: EXPERIMENTAL
Intervention: EGFR-positive tumors
Number of subjects: 68
Study 2690971 — intervention group
Group type: EXPERIMENTAL
Intervention: EGFR+/ER- patients
Number of subjects: 68
Study 2690971 — intervention group
Group type: EXPERIMENTAL
Intervention: EGFR levels
Number of subjects: 68
Study 776537 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg flupenthixol 2 to 4-times daily for 2 weeks
Number of subjects: 43
Study 776537 — intervention group
Group type: COMPARATOR
Intervention: Identical placebo tablets 2 to 4-times daily for 2 weeks
Number of subjects: 43
Study 31311366 — intervention group
Group type: EXPERIMENTAL
Intervention: AlloDerm myringoplasty (Group 1)
Number of subjects: 61
Study 31311366 — intervention group
Group type: COMPARATOR
Intervention: Perichondrium myringoplasty (Group 2)
Number of subjects: 61
Study 29083206 — intervention group
Group type: EXPERIMENTAL
Intervention: SSSR-F (Strengthening Same-Sex Relationships Program, Female version)
Number of subjects: 37
Study 25040180 — intervention group
Group type: EXPERIMENTAL
Intervention: CLNP/BPO 3·0% twice daily
Number of subjects: 800
Study 25040180 — intervention group
Group type: EXPERIMENTAL
Intervention: CLNP/BPO 3·0% once daily
Number of subjects: 800
Study 23224626 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium (500 mg/day) and vitamin D (60,000 IU/3 months)
Number of subjects: 31
Study 23224626 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium (500 mg/day), vitamin D (60,000 IU/3 months), and zinc (as per Indian Recommended Allowance)
Number of subjects: 31
Study 23224626 — intervention group
Group type: COMPARATOR
Intervention: Growth hormone therapy
Number of subjects: 31
Study 21613427 — intervention group
Group type: EXPERIMENTAL
Intervention: RV apical pacing
Number of subjects: 108
Study 21613427 — intervention group
Group type: COMPARATOR
Intervention: BIV pacing
Number of subjects: 108
Study 19249659 — intervention group
Group type: EXPERIMENTAL
Intervention: Zhi Byed 11 (ZB11)
Number of subjects: 967
Study 19249659 — intervention group
Group type: COMPARATOR
Intervention: Misoprostol
Number of subjects: 967
Study 16896957 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine patch
Number of subjects: 36
Study 16896957 — intervention group
Group type: COMPARATOR
Intervention: Placebo patch
Number of subjects: 36
Study 15333468 — intervention group
Group type: EXPERIMENTAL
Intervention: ACCalpha haplotype associated with breast cancer risk
Number of subjects: 453
Study 15333468 — intervention group
Group type: EXPERIMENTAL
Intervention: Common ACCalpha alleles
Number of subjects: 453
Study 15333468 — intervention group
Group type: EXPERIMENTAL
Intervention: Three other haplotypes
Number of subjects: 453
Study 15333468 — intervention group
Group type: EXPERIMENTAL
Intervention: Mutations in the ACCalpha gene
Number of subjects: 453
Study 11295650 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (200 microg twice daily for 6 weeks)
Number of subjects: 19
Study 11295650 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 7498360 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human erythropoietin (rhEpo) treatment; specific dosage and duration not mentioned.
Number of subjects: 18
Study 7498360 — intervention group
Group type: COMPARATOR
Intervention: No treatment (control group); 12 patients without PB CFU-E.
Number of subjects: 18
Study 7498360 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of PB CFU-E; no specific treatment mentioned.
Number of subjects: 18
Study 2023754 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulse therapy (prednisolone acetate 1% drops hourly and a single intravenous pulse of 500 mg methylprednisolone)
Number of subjects: 48
Study 2023754 — intervention group
Group type: COMPARATOR
Intervention: Oral therapy (same topical therapy plus oral prednisone 60 to 80 mg daily)
Number of subjects: 48
Study 2023754 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulse therapy (for patients treated early, less than or equal to 8 days)
Number of subjects: 48
Study 2023754 — intervention group
Group type: COMPARATOR
Intervention: Oral therapy (for patients treated early, less than or equal to 8 days)
Number of subjects: 48
Study 2023754 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulse therapy
Number of subjects: 48
Study 2023754 — intervention group
Group type: COMPARATOR
Intervention: Oral therapy
Number of subjects: 48
Study 7032681 — intervention group
Group type: EXPERIMENTAL
Intervention: Corynebacterium parvum combined with radiation therapy (4 mg/m2 into tumor-bearing lymph nodes and 2, 2, 4, 4, and 4 mg/m2 intravenously at specified days)
Number of subjects: 57
Study 7032681 — intervention group
Group type: COMPARATOR
Intervention: Radiation therapy alone
Number of subjects: 57
Study 30264631 — intervention group
Group type: EXPERIMENTAL
Intervention: Splint group (n=39)
Number of subjects: 80
Study 30264631 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=41)
Number of subjects: 80
Study 28739062 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervical collar intervention after operation, kept on until mobilization
Number of subjects: 120
Study 28739062 — intervention group
Group type: COMPARATOR
Intervention: Control group with no head and neck immobilization
Number of subjects: 120
Study 26397834 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct Trocar Insertion (DTI)
Number of subjects: 81
Study 26397834 — intervention group
Group type: COMPARATOR
Intervention: Veress Needle Insertion (VNI)
Number of subjects: 81
Study 23577903 — intervention group
Group type: EXPERIMENTAL
Intervention: In vivo (IV) approach
Number of subjects: 143
Study 23577903 — intervention group
Group type: EXPERIMENTAL
Intervention: Distance learning (DL) approach
Number of subjects: 143
Study 23577903 — intervention group
Group type: COMPARATOR
Intervention: Control condition (C)
Number of subjects: 143
Study 21289525 — intervention group
Group type: EXPERIMENTAL
Intervention: Bazedoxifene 5 mg
Number of subjects: 494
Study 21289525 — intervention group
Group type: EXPERIMENTAL
Intervention: Bazedoxifene 10 mg
Number of subjects: 494
Study 21289525 — intervention group
Group type: EXPERIMENTAL
Intervention: Bazedoxifene 20 mg
Number of subjects: 494
Study 21289525 — intervention group
Group type: EXPERIMENTAL
Intervention: Raloxifene 60 mg
Number of subjects: 494
Study 21289525 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 494
Study 18777173 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical miconazole oral gel (85 mg x 3, 3 days)
Number of subjects: 12
Study 18777173 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral voriconazole (400 mg x 2, 1st day, 200 mg x 2, 2nd day)
Number of subjects: 12
Study 18777173 — intervention group
Group type: COMPARATOR
Intervention: No pretreatment (control)
Number of subjects: 12
Study 17725472 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser therapy plus exercise
Number of subjects: 61
Study 14747427 — intervention group
Group type: EXPERIMENTAL
Intervention: Aripiprazole 5 mg, 10 mg, 15 mg, 20 mg once daily (Study 1)
Number of subjects: 48
Study 14747427 — intervention group
Group type: EXPERIMENTAL
Intervention: Aripiprazole titrated from 10 to 30 mg/day (Study 2)
Number of subjects: 48
Study 14747427 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Study 1 and Study 2)
Number of subjects: 48
Study 11393383 — intervention group
Group type: EXPERIMENTAL
Intervention: Spirapril 6 mg daily
Number of subjects: 60
Study 11393383 — intervention group
Group type: EXPERIMENTAL
Intervention: Isradipine 5 mg daily
Number of subjects: 60
Study 11393383 — intervention group
Group type: EXPERIMENTAL
Intervention: Spirapril 3 mg and Isradipine 2.5 mg daily
Number of subjects: 60
Study 11393383 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy (Spirapril and Isradipine)
Number of subjects: 60
Study 9605896 — intervention group
Group type: COMPARATOR
Intervention: Abstinence intervention
Number of subjects: 659
Study 9605896 — intervention group
Group type: COMPARATOR
Intervention: Safer-sex intervention
Number of subjects: 659
Study 9605896 — intervention group
Group type: COMPARATOR
Intervention: Control intervention
Number of subjects: 659
Study 9950664 — intervention group
Group type: EXPERIMENTAL
Intervention: Slow pathway ablation in group 1 (continuous AVN conduction curves)
Number of subjects: 136
Study 9950664 — intervention group
Group type: EXPERIMENTAL
Intervention: Slow pathway ablation in group 2 (discontinuous AVN conduction curves)
Number of subjects: 136
Study 9950664 — intervention group
Group type: EXPERIMENTAL
Intervention: A1A2A3 stimulation
Number of subjects: 136
Study 2565917 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxazosin
Number of subjects: 30
Study 2565917 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 332217 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg xipamid
Number of subjects: 20
Study 332217 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg xipamid
Number of subjects: 20
Study 332217 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 31811128 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised high-dose primaquine
Number of subjects: 1299
Study 31811128 — intervention group
Group type: COMPARATOR
Intervention: No primaquine treatment
Number of subjects: 1299
Study 28941934 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrate supplementation (140 ml of concentrated beetroot juice)
Number of subjects: 13
Study 28941934 — intervention group
Group type: COMPARATOR
Intervention: Placebo (nitrate-depleted beetroot juice)
Number of subjects: 13
Study 28941934 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrate supplementation
Number of subjects: 13
Study 26467594 — intervention group
Group type: EXPERIMENTAL
Intervention: Urokinase
Number of subjects: 171
Study 26467594 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 171
Study 23578495 — intervention group
Group type: EXPERIMENTAL
Intervention: Method of inter‐active problem solving targeted at the functioning of the teams
Number of subjects: 54
Study 23578495 — intervention group
Group type: EXPERIMENTAL
Intervention: Method for developing professional practice centred on individual
Number of subjects: 54
Study 22024266 — intervention group
Group type: EXPERIMENTAL
Intervention: AlphaScope
Number of subjects: 150
Study 22024266 — intervention group
Group type: COMPARATOR
Intervention: LBH
Number of subjects: 150
Study 19491535 — intervention group
Group type: EXPERIMENTAL
Intervention: Liraglutide 1.8 mg once daily
Number of subjects: 0
Study 19491535 — intervention group
Group type: COMPARATOR
Intervention: Rosiglitazone plus glimepiride
Number of subjects: 0
Study 19491535 — intervention group
Group type: COMPARATOR
Intervention: Glimepiride
Number of subjects: 0
Study 19491535 — intervention group
Group type: EXPERIMENTAL
Intervention: Liraglutide or glimepiride
Number of subjects: 0
Study 16479244 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil (group 1)
Number of subjects: 101
Study 16479244 — intervention group
Group type: COMPARATOR
Intervention: Control (group 2)
Number of subjects: 101
Study 16479244 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil administration
Number of subjects: 101
Study 15553660 — intervention group
Group type: EXPERIMENTAL
Intervention: Erdosteine (300 mg b.i.d. for 8 months)
Number of subjects: 155
Study 15553660 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 155
Study 11761117 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose group (168‐255 microg of each phthalate)
Number of subjects: 24
Study 11761117 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose group (336 to 510 microg of each phthalate)
Number of subjects: 24
Study 11761117 — intervention group
Group type: COMPARATOR
Intervention: Control group (no dose)
Number of subjects: 24
Study 9247840 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine 1,000 mg daily over 20 days
Number of subjects: 12
Study 9247840 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine treatment with metamizol doses of 750 mg and 1,500 mg
Number of subjects: 12
Study 9247840 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine
Number of subjects: 12
Study 7506164 — intervention group
Group type: EXPERIMENTAL
Intervention: nimesulide (200mg twice daily)
Number of subjects: 76
Study 7506164 — intervention group
Group type: EXPERIMENTAL
Intervention: ketoprofen (100mg twice daily)
Number of subjects: 76
Study 2428719 — intervention group
Group type: EXPERIMENTAL
Intervention: Depot secretin therapy (800 CU by subcutaneous injection twice daily for 7 days)
Number of subjects: 0
Study 2428719 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 29935790 — intervention group
Group type: EXPERIMENTAL
Intervention: Calvarial bone harvesting
Number of subjects: 20
Study 29935790 — intervention group
Group type: EXPERIMENTAL
Intervention: Anterior iliac crest bone harvesting
Number of subjects: 20
Study 26179237 — intervention group
Group type: EXPERIMENTAL
Intervention: Dacomitinib 45 mg alone under fasting conditions
Number of subjects: 24
Study 26179237 — intervention group
Group type: EXPERIMENTAL
Intervention: Dacomitinib 45 mg after a high-fat, high-calorie meal
Number of subjects: 24
Study 26179237 — intervention group
Group type: COMPARATOR
Intervention: Dacomitinib 45 mg coadministered with rabeprazole 40 mg under fasting conditions
Number of subjects: 24
Study 24996856 — intervention group
Group type: EXPERIMENTAL
Intervention: EVAA appliance
Number of subjects: 34
Study 24996856 — intervention group
Group type: EXPERIMENTAL
Intervention: Activator appliance
Number of subjects: 34
Study 24996856 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 34
Study 22718380 — intervention group
Group type: EXPERIMENTAL
Intervention: Haemodynamic evaluation by ICG (HD)
Number of subjects: 82
Study 19277623 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamsulosin 0.4 mg once daily for 2 weeks
Number of subjects: 154
Study 19277623 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 2 weeks
Number of subjects: 154
Study 19277623 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamsulosin
Number of subjects: 154
Study 19277623 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 154
Study 17848492 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel clinical trial design (sequential parallel design)
Number of subjects: 0
Study 17848492 — intervention group
Group type: COMPARATOR
Intervention: Standard clinical trial design (conventional two arm)
Number of subjects: 0
Study 15470214 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel and estramustine
Number of subjects: 770
Study 15470214 — intervention group
Group type: COMPARATOR
Intervention: Mitoxantrone and prednisone
Number of subjects: 770
Study 11406729 — intervention group
Group type: EXPERIMENTAL
Intervention: Warfarin 1 mg
Number of subjects: 40
Study 11406729 — intervention group
Group type: EXPERIMENTAL
Intervention: Warfarin 2 mg
Number of subjects: 40
Study 11406729 — intervention group
Group type: EXPERIMENTAL
Intervention: Warfarin 3 mg
Number of subjects: 40
Study 11406729 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 9720470 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefaclor (40 mg/kg/day for 10 days)
Number of subjects: 205
Study 9720470 — intervention group
Group type: COMPARATOR
Intervention: Cefuroxime axetil (30 mg/kg/day for 10 days)
Number of subjects: 205
Study 9720470 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefaclor
Number of subjects: 205
Study 9720470 — intervention group
Group type: COMPARATOR
Intervention: Cefuroxime axetil
Number of subjects: 205
Study 8113850 — intervention group
Group type: EXPERIMENTAL
Intervention: Western surgical resection with limited lymphadenectomy (R1)
Number of subjects: 237
Study 8113850 — intervention group
Group type: EXPERIMENTAL
Intervention: Japanese surgical resection with extended lymphadenectomy (R2)
Number of subjects: 237
Study 3053887 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactitol (10 g/6 h)
Number of subjects: 25
Study 3053887 — intervention group
Group type: COMPARATOR
Intervention: Lactulose (15 ml/6 h, 66% w/v, containing 10 g of lactulose)
Number of subjects: 25
Study 3053887 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactitol
Number of subjects: 25
Study 3053887 — intervention group
Group type: COMPARATOR
Intervention: Lactulose
Number of subjects: 25
Study 7142087 — intervention group
Group type: EXPERIMENTAL
Intervention: Single dose of 500 mg cefadroxil
Number of subjects: 0
Study 7142087 — intervention group
Group type: EXPERIMENTAL
Intervention: Single dose of 1 g cefadroxil
Number of subjects: 0
Study 7142087 — intervention group
Group type: EXPERIMENTAL
Intervention: Three repeated doses of 500 mg cefadroxil
Number of subjects: 0
Study 7142087 — intervention group
Group type: EXPERIMENTAL
Intervention: Two repeated doses of 1 g cefadroxil
Number of subjects: 0
Study 31262022 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary interventions; specific interventions not detailed in the abstract.
Number of subjects: 0
Study 29043493 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 week physical activity intervention (four sessions delivered over a 6-week period by a trained physiotherapist)
Number of subjects: 0
Study 29043493 — intervention group
Group type: COMPARATOR
Intervention: Control group (physical activity information leaflet)
Number of subjects: 0
Study 25542912 — intervention group
Group type: EXPERIMENTAL
Intervention: Intention to return to smoking
Number of subjects: 382
Study 25542912 — intervention group
Group type: EXPERIMENTAL
Intervention: Demographic and smoking factors
Number of subjects: 382
Study 24799467 — intervention group
Group type: EXPERIMENTAL
Intervention: MyVax (Id coupled to KLH plus GM-CSF), n=195
Number of subjects: 287
Study 24799467 — intervention group
Group type: COMPARATOR
Intervention: Control immunotherapy (KLH plus GM-CSF)
Number of subjects: 287
Study 22691628 — intervention group
Group type: EXPERIMENTAL
Intervention: Masitinib (3 to 6 mg/kg/day for at least 12 months)
Number of subjects: 35
Study 22691628 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35